Septerna (NASDAQ:SEPN) Sets New 12-Month Low – Here’s Why

Septerna, Inc. (NASDAQ:SEPN) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $15.83 and last traded at $16.16, with a volume of 177094 shares changing hands. The stock had previously closed at $18.48.

Analyst Ratings Changes

SEPN has been the subject of several research analyst reports. TD Cowen started coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company. Cantor Fitzgerald began coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price target on the stock. Wells Fargo & Company assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price objective for the company. Finally, JPMorgan Chase & Co. began coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price objective for the company.

Septerna Price Performance

The company’s 50 day simple moving average is $21.88.

Hedge Funds Weigh In On Septerna

A hedge fund recently bought a new stake in Septerna stock. SG Americas Securities LLC acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,095 shares of the company’s stock, valued at approximately $185,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.